Business
Dr. Anke M. Schulte Joins Sernova Global Advisory Board
(via TheNewswire) Veteran Pharmaceutical Executive in Regenerative Medicin...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Dr. Anke M. Schulte Joins Sernova Global Advisory Board(via TheNewswire)\n \n \nVeteran Pharmaceutical Executive in Regenerative Medicine Therapeutics to Contribute Corporate Development/ Strategic Expertise to Sernova\n\n \n \nLONDON, ONTARIO - TheNewswire - July 16, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical- stage regenerative medicine company, announced today the creation of a Global Advisory Board, and the addition to the advisory board of Dr. Anke M. Schulte. Dr. Schulte is an internationally acclaimed expert in diabetes and cell therapy regenerative medicine and a 19-year veteran of Sanofi, a global pharmaceutical leader. \n\n\n \nSernova Global Advisory Board members will provide knowledge, experience and strategic insights to support the continued development and future commercialization of Sernova's novel regenerative medicine cell therapy therapeutics platform. They will also provide advice on our clinical development programs, expansion plans for the Company, acquisition of additional technologies, as well as pharma collaborations and partnering.\n\n \n \nSaid Dr. Philip Toleikis, President and CEO of Sernova, \"Through years of scientific teamwork, persistence and dedication, the Sernova team has developed, refined and systematically de-risked our cell therapy therapeutics platform by generating strong preclinical data and an expanding confirmatory human clinical data set for our implantable Cell Pouch(TM) device and immune protected cell technologies. We believe the new Global Advisory Board, which will include international experts who are visionary leaders, will help us in transforming the promise and potential of our platform into a 'functional cure' for a number of serious chronic diseases.\" \n\n\n \nToleikis added, \"As its inaugural member, Dr. Schulte brings an impressive career of excellence in innovation, experience and passion in the field, and importantly has witnessed the potential of Sernova's diabetes technologies. Dr. Schulte's 19 years of experience in progressive positions at Sanofi, in islet biology and in the regenerative medicine cell therapy field will be invaluable in contributing to our strategic decision making as we continue to advance our technologies to commercialization.\" \n\n\n \n\"In the capacity of regenerative medicine lead with Sanofi, overseeing Type 1 diab...